Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7180693

Cc1ccc(C)c(PC(=O)c2c(C)cccc2C)c1.[Li]

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ S1PR4 O95977 9/20 0.38
▸ CYP1A2 P05177 3/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ ACHE P22303 1/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ S1PR2 O95136 1/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180684 0.97 S1PR4 (0.38) S1PR4CYP1A2CYP2C19ACHECYP2A6
Lithium SCHEMBL7189944 0.90 TYK2 (0.39) S1PR4GAAALDH1A1
Lithium SCHEMBL7189034 0.88 TP53 (0.35) CYP2A6GAAMEN1ALDH1A1HPGD
Lithium SCHEMBL7177510 0.87 ALDH1A1 (0.39) CYP1A2CYP2C19GAAMEN1ALDH1A1
Lithium SCHEMBL7180446 0.87 NFE2L2 (0.36) S1PR4CYP1A2CYP2A6GAAPARP1
SCHEMBL7189939 0.86 TYK2 (0.39) S1PR4GAAALDH1A1
SCHEMBL10870076 0.85 ALDH1A1 (0.40) CYP1A2CYP2C19GAAMEN1ALDH1A1
SCHEMBL7189025 0.85 TP53 (0.35) CYP2A6GAAMEN1ALDH1A1HPGD
SCHEMBL7177506 0.84 ALDH1A1 (0.39) CYP1A2CYP2C19GAAMEN1ALDH1A1
SCHEMBL7180437 0.83 NFE2L2 (0.36) S1PR4CYP1A2CYP2A6GAAPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1200943-C Organometallic acyl-aryl phosphine CIBA SC HOLDING AG (CH) 2005-05-11 — — CN disclosed
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed
CN-1308081-A Organometallic acyl-aryl phosphine CIBA SC HOLDING AG (CH) 2001-08-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 S1PR4 771/4885CYP1A2 1595/4885CYP2C19 1820/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 S1PR4 826/4885CYP1A2 2020/4885CYP2C19 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.